AVE8062	0	7	B-Drug_or_compound
:	7	8	O
a	9	10	O
new	11	14	O
combretastatin	15	29	B-Drug_or_compound
derivative	30	40	O
vascular	41	49	B-Multi-tissue_structure
disrupting	50	60	O
agent	61	66	O
.	66	67	O

Angiogenesis	69	81	O
has	82	85	O
an	86	88	O
essential	89	98	O
role	99	103	O
in	104	106	O
promoting	107	116	O
and	117	120	O
supporting	121	131	O
tumor	132	137	B-Pathological_formation
growth	138	144	O
and	145	148	O
it	149	151	O
is	152	154	O
an	155	157	O
important	158	167	O
therapeutic	168	179	O
target	180	186	O
.	186	187	O

The	188	191	O
tumor	192	197	B-Multi-tissue_structure
vascular	198	206	I-Multi-tissue_structure
network	207	214	I-Multi-tissue_structure
is	215	217	O
the	218	221	O
result	222	228	O
of	229	231	O
pro	232	235	O
-	235	236	O
angiogenic	236	246	O
and	247	250	O
inhibitory	251	261	O
factors	262	269	O
as	270	272	O
well	273	277	O
as	278	280	O
of	281	283	O
the	284	287	O
interaction	288	299	O
between	300	307	O
endothelial	308	319	B-Cell
cells	320	325	I-Cell
and	326	329	O
extracellular	330	343	B-Cellular_component
matrix	344	350	I-Cellular_component
.	350	351	O

Different	352	361	O
antiangiogenic	362	376	O
therapeutics	377	389	O
have	390	394	O
been	395	399	O
developed	400	409	O
to	410	412	O
improve	413	420	O
tumor	421	426	B-Pathological_formation
control	427	434	O
through	435	442	O
vascular	443	451	B-Drug_or_compound
-	451	452	I-Drug_or_compound
targeting	452	461	I-Drug_or_compound
agents	462	468	I-Drug_or_compound
(	469	470	O
VTA	470	473	B-Drug_or_compound
)	473	474	O
.	474	475	O

VTAs	476	480	B-Drug_or_compound
can	481	484	O
be	485	487	O
divided	488	495	O
into	496	500	O
two	501	504	O
groups	505	511	O
:	511	512	O
antiangiogenic	513	527	B-Drug_or_compound
agents	528	534	I-Drug_or_compound
and	535	538	O
vascular	539	547	B-Drug_or_compound
-	547	548	I-Drug_or_compound
disrupting	548	558	I-Drug_or_compound
agents	559	565	I-Drug_or_compound
(	566	567	O
VDAs	567	571	B-Drug_or_compound
)	571	572	O
.	572	573	O

VTAs	574	578	B-Drug_or_compound
inhibit	579	586	O
specific	587	595	O
factors	596	603	O
required	604	612	O
to	613	615	O
induce	616	622	O
and	623	626	O
direct	627	633	O
the	634	637	O
angiogenic	638	648	O
process	649	656	O
,	656	657	O
with	658	662	O
major	663	668	O
activity	669	677	O
against	678	685	O
small	686	691	O
tumor	692	697	B-Pathological_formation
masses	698	704	I-Pathological_formation
and	705	708	O
at	709	711	O
the	712	715	O
tumor	716	721	B-Tissue
periphery	722	731	I-Tissue
,	731	732	O
encompassing	733	745	O
monoclonal	746	756	O
antibodies	757	767	O
and	768	771	O
small	772	777	O
molecules	778	787	O
inhibitors	788	798	O
of	799	801	O
the	802	805	O
tyrosine	806	814	O
kinase	815	821	O
domain	822	828	O
of	829	831	O
the	832	835	O
VEGF	836	840	B-Gene_or_gene_product
receptor	841	849	I-Gene_or_gene_product
.	849	850	O

VDAs	851	855	B-Drug_or_compound
specifically	856	868	O
target	869	875	O
and	876	879	O
destroy	880	887	O
well	888	892	O
-	892	893	O
established	893	904	O
tumor	905	910	B-Multi-tissue_structure
vessels	911	918	I-Multi-tissue_structure
with	919	923	O
ischemia	924	932	O
and	933	936	O
destruction	937	948	O
of	949	951	O
large	952	957	O
masses	958	964	B-Pathological_formation
with	965	969	O
central	970	977	O
hemorrhagic	978	989	O
necrosis	990	998	O
and	999	1002	O
survival	1003	1011	O
of	1012	1014	O
a	1015	1016	O
thin	1017	1021	O
peripheral	1022	1032	B-Pathological_formation
tumor	1033	1038	I-Pathological_formation
layer	1039	1044	I-Pathological_formation
.	1044	1045	O

VDAs	1046	1050	B-Drug_or_compound
can	1051	1054	O
be	1055	1057	O
divided	1058	1065	O
into	1066	1070	O
biologics	1071	1080	O
,	1080	1081	O
such	1082	1086	O
as	1087	1089	O
ligand	1090	1096	O
-	1096	1097	O
based	1097	1102	O
,	1102	1103	O
and	1104	1107	O
small	1108	1113	O
-	1113	1114	O
molecule	1114	1122	O
agents	1123	1129	O
;	1129	1130	O
this	1131	1135	O
second	1136	1142	O
group	1143	1148	O
includes	1149	1157	O
small	1158	1163	B-Drug_or_compound
-	1163	1164	I-Drug_or_compound
molecule	1164	1172	I-Drug_or_compound
VDAs	1173	1177	I-Drug_or_compound
like	1178	1182	O
flavonoids	1183	1193	B-Drug_or_compound
,	1193	1194	O
such	1195	1199	O
as	1200	1202	O
5	1203	1204	B-Drug_or_compound
,	1204	1205	I-Drug_or_compound
6	1205	1206	I-Drug_or_compound
-	1206	1207	I-Drug_or_compound
dimethylxanthenone	1207	1225	I-Drug_or_compound
-	1225	1226	I-Drug_or_compound
4	1226	1227	I-Drug_or_compound
-	1227	1228	I-Drug_or_compound
acetic	1228	1234	I-Drug_or_compound
acid	1235	1239	I-Drug_or_compound
(	1240	1241	O
DMXAA	1241	1246	B-Drug_or_compound
)	1246	1247	O
,	1247	1248	O
and	1249	1252	O
microtubule	1253	1264	B-Drug_or_compound
-	1264	1265	I-Drug_or_compound
destabilizing	1265	1278	I-Drug_or_compound
agents	1279	1285	I-Drug_or_compound
.	1285	1286	O

In	1287	1289	O
this	1290	1294	O
review	1295	1301	O
we	1302	1304	O
will	1305	1309	O
discuss	1310	1317	O
the	1318	1321	O
mechanism	1322	1331	O
of	1332	1334	O
action	1335	1341	O
,	1341	1342	O
as	1343	1345	O
well	1346	1350	O
as	1351	1353	O
the	1354	1357	O
preclinical	1358	1369	O
and	1370	1373	O
clinical	1374	1382	O
results	1383	1390	O
,	1390	1391	O
of	1392	1394	O
one	1395	1398	O
of	1399	1401	O
the	1402	1405	O
most	1406	1410	O
promising	1411	1420	O
antitubulin	1421	1432	B-Drug_or_compound
agents	1433	1439	I-Drug_or_compound
:	1439	1440	O
the	1441	1444	O
combretastatin	1445	1459	B-Drug_or_compound
A4	1460	1462	I-Drug_or_compound
-	1462	1463	I-Drug_or_compound
phosphate	1463	1472	I-Drug_or_compound
derivative	1473	1483	I-Drug_or_compound
,	1483	1484	O
AVE8062A	1485	1493	B-Drug_or_compound
.	1493	1494	O

